Overview

CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.
Phase:
Phase 1
Details
Lead Sponsor:
ARCAGY/ GINECO GROUP
Treatments:
Cisplatin
Irinotecan